Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- Kyowa Kirin’s 1st Half Pharmaceuticals Business Log 9.2% Sales Rise, but Operating Profits Fall
July 30, 2012
- US FDA Withholds Approval for Injectafer Due to Manufacturing Facility Issues: Daiichi Sankyo
July 30, 2012
- Approval for Once-Monthly Aripiprazole Hits Snag in US: Otsuka
July 30, 2012
- DSP, Nitto Denko Initiate PII Studies for Transdermal Patch Lonasen
July 30, 2012
- Eisai Receives Approval in Europe for Antiepileptic Perampanel; Launch in September
July 30, 2012
- Market Exclusivity for Lunesta Extended 6 Months in the US: DSP
July 30, 2012
- Celgene Initiates PII Trial in Japan for Revlimid in Treatment-Naïve Patients with Multiple Myeloma
July 30, 2012
- Pfizer Japan Files NDA for Prevnar 13 for Infant Use
July 30, 2012
- Kobayashi Kako Completes Construction of Anticancer Drug Manufacturing Facility
July 30, 2012
- Alfresa Launches Advanced Temperature-controlled Distribution Service
July 30, 2012
- Chugai’s 1st-Half Sales Excluding Tamiflu Down 0.3% in Japan as Mircera Slumps
July 30, 2012
- Chugai Had Tough Start in Final Year of Midterm Plan: Chairman Nagayama
July 30, 2012
- Takeda Initiates PIII Trial for Anticancer Agent Motesanib in Asia
July 27, 2012
- Serum Ca Levels Show No Increase in Coadministration of Forteo, Activated Vitamin D3: Eli Lilly Japan
July 27, 2012
- Keizai Doyukai Chairman Hasegawa Instructs Takeda to Create Countermeasures for Risk of Violence in Emerging Countries
July 27, 2012
- Tarceva Shows No Significant Difference in PIII Study, Indication for Hepatoma Difficult: Astellas
July 26, 2012
- Kyowa Hakko Bio’s Subsidiary Completes Drug Substance Production Facility Conforming to Japan, US, Europe GMPs
July 26, 2012
- Takeda Receives Positive Opinion from CHMP on Adcetris
July 26, 2012
- Taiho Licenses Anti-Allergy Drug from Faes Farma in Japan
July 26, 2012
- Sandoz Launches Generic Claritin
July 26, 2012
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…